Cargando…

Characterizing the mechanism behind the progression of NAFLD to hepatocellular carcinoma

Hepatocellular carcinoma (HCC) developed in non-alcoholic fatty liver disease (NAFLD) individuals presents substantial clinical and biological characteristics, which remain to be elucidated. Its occurrence in noncirrhotic patients raises issues regarding surveillance strategies, which cannot be cons...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nahon, Pierre, Allaire, Manon, Nault, Jean-Charles, Paradis, Valérie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Future Medicine Ltd 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7907968/ https://www.ncbi.nlm.nih.gov/pubmed/33680428 http://dx.doi.org/10.2217/hep-2020-0017

Ejemplares similares

Molecular Determinants of Prognosis in Hepatocellular Carcinoma
por: Nault, Jean-Charles
Publicado: (2014)

Immunotherapy for NAFLD and NAFLD-related hepatocellular carcinoma
por: Jeong, Seogsong, et al.
Publicado: (2023)

NAFLD‐related hepatocellular carcinoma: The growing challenge
por: Shah, Pir Ahmad, et al.
Publicado: (2023)

Genetics of Hepatocellular Carcinoma: From Tumor to Circulating DNA
por: Campani, Claudia, et al.
Publicado: (2023)

From congestive hepatopathy to hepatocellular carcinoma, how can we improve patient management?
por: Sessa, Anna, et al.
Publicado: (2021)

Prevalence of the Absence of Cirrhosis in Subjects with NAFLD-Associated Hepatocellular Carcinoma
por: Castellana, Marco, et al.
Publicado: (2021)

The Emerging Factors and Treatment Options for NAFLD-Related Hepatocellular Carcinoma
por: Zhang, Chunye, et al.
Publicado: (2021)

Portal hypertension and hepatocellular carcinoma: Navigating uncharted waters
por: Sidali, Sabrina, et al.
Publicado: (2022)

Stratification of Hepatocellular Carcinoma Risk Following HCV Eradication or HBV Control
por: Nahon, Pierre, et al.
Publicado: (2021)

Impact of Extended Use of Ablation Techniques in Cirrhotic Patients with Hepatocellular Carcinoma: A Cost-Effectiveness Analysis
por: Ramtohul, Toulsie, et al.
Publicado: (2022)

Mechanisms of hepatocellular carcinoma progression
por: Ogunwobi, Olorunseun O, et al.
Publicado: (2019)

New frontiers in liver resection for hepatocellular carcinoma
por: Allaire, Manon, et al.
Publicado: (2020)

New concepts in the treatment of hepatocellular carcinoma
por: Sidali, Sabrina, et al.
Publicado: (2022)

Molecular Classification of Hepatocellular Adenomas
por: Nault, Jean Charles, et al.
Publicado: (2013)

Hepatitis B virus integrations promote local and distant oncogenic driver alterations in hepatocellular carcinoma
por: Péneau, Camille, et al.
Publicado: (2022)

Dynamic of systemic immunity and its impact on tumor recurrence after radiofrequency ablation of hepatocellular carcinoma
por: Rochigneux, Philippe, et al.
Publicado: (2019)

Hepatocellular carcinoma: Mechanisms of progression and immunotherapy
por: Jiang, Yu, et al.
Publicado: (2019)

Characterization of two types of intranuclear hepatocellular inclusions in NAFLD
por: Schwertheim, Suzan, et al.
Publicado: (2020)

New insights into the pathophysiology and clinical care of rare primary liver cancers
por: Gigante, Elia, et al.
Publicado: (2020)

Sulfatase 2 Along with Syndecan 1 and Glypican 3 Serum Levels are Associated with a Prognostic Value in Patients with Alcoholic Cirrhosis-Related Advanced Hepatocellular Carcinoma
por: Mouhoubi, Nesrine, et al.
Publicado: (2022)

NAFLD-Associated HCC: Progress and Opportunities
por: Geh, Daniel, et al.
Publicado: (2021)

Sex difference in liver diseases: How preclinical models help to dissect the sex-related mechanisms sustaining NAFLD and hepatocellular carcinoma
por: Smiriglia, Alfredo, et al.
Publicado: (2023)

NAFLD: Mechanisms, Treatments, and Biomarkers
por: Nassir, Fatiha
Publicado: (2022)

Imaging and histological features of tumor biopsy sample predict aggressive intrasegmental recurrence of hepatocellular carcinoma after radiofrequency ablation
por: Gigante, Elia, et al.
Publicado: (2022)

Molecular classification of hepatocellular adenomas: impact on clinical practice
por: Védie, Anne-Laure, et al.
Publicado: (2018)

Characterization of transcriptional modules related to fibrosing-NAFLD progression
por: Lou, Yi, et al.
Publicado: (2017)

Senescence in HBV-, HCV- and NAFLD- Mediated Hepatocellular Carcinoma and Senotherapeutics: Current Evidence and Future Perspective
por: Giannakoulis, Vassilis G., et al.
Publicado: (2021)

An Overview of Hepatocellular Carcinoma Surveillance Focusing on Non-Cirrhotic NAFLD Patients: A Challenge for Physicians
por: Cespiati, Annalisa, et al.
Publicado: (2023)

Hepatocellular carcinoma with portal invasion, still a place for liver surgery in the era of immunotherapy?
por: Giudicelli, Héloïse, et al.
Publicado: (2022)

The Common Mechanisms of Sarcopenia and NAFLD
por: Zhai, Yu, et al.
Publicado: (2017)

Somatic mutations activating STAT3 in human inflammatory hepatocellular adenomas
por: Pilati, Camilla, et al.
Publicado: (2011)

Impact of COVID-19 on the management of hepatocellular carcinoma in a high-prevalence area
por: Amaddeo, Giuliana, et al.
Publicado: (2020)

Altered serum acylcarnitine profile is associated with the status of nonalcoholic fatty liver disease (NAFLD) and NAFLD-related hepatocellular carcinoma
por: Enooku, Kenichiro, et al.
Publicado: (2019)

Adaptive immunity: an emerging player in the progression of NAFLD
por: Sutti, Salvatore, et al.
Publicado: (2019)

Mechanisms behind context-dependent role of glucocorticoids in breast cancer progression
por: Butz, Henriett, et al.
Publicado: (2022)

Glucagon is associated with NAFLD inflammatory progression in type 2 diabetes, not with NAFLD fibrotic progression
por: Wang, Yuying, et al.
Publicado: (2021)

Molecular mechanisms behind mRNA localization in axons
por: Turner-Bridger, Benita, et al.
Publicado: (2020)

What to do about hepatocellular carcinoma: Recommendations for health authorities from the International Liver Cancer Association
por: Allaire, Manon, et al.
Publicado: (2022)

Histone Modifications in NAFLD: Mechanisms and Potential Therapy
por: Shi, Yulei, et al.
Publicado: (2023)

NAFLD polygenic risk score and risk of hepatocellular carcinoma in an East Asian population
por: Thomas, Claire E., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_v4enno3meu1ghee4q0llsvon87